- English
- Chinese
- French
- German
- Portuguese
- Spanish
- Russian
- Japanese
- Korean
- Arabic
- Irish
- Greek
- Turkish
- Italian
- Danish
- Romanian
- Indonesian
- Czech
- Afrikaans
- Swedish
- Polish
- Basque
- Catalan
- Esperanto
- Hindi
- Lao
- Albanian
- Amharic
- Armenian
- Azerbaijani
- Belarusian
- Bengali
- Bosnian
- Bulgarian
- Cebuano
- Chichewa
- Corsican
- Croatian
- Dutch
- Estonian
- Filipino
- Finnish
- Frisian
- Galician
- Georgian
- Gujarati
- Haitian
- Hausa
- Hawaiian
- Hebrew
- Hmong
- Hungarian
- Icelandic
- Igbo
- Javanese
- Kannada
- Kazakh
- Khmer
- Kurdish
- Kyrgyz
- Latin
- Latvian
- Lithuanian
- Luxembou..
- Macedonian
- Malagasy
- Malay
- Malayalam
- Maltese
- Maori
- Marathi
- Mongolian
- Burmese
- Nepali
- Norwegian
- Pashto
- Persian
- Punjabi
- Serbian
- Sesotho
- Sinhala
- Slovak
- Slovenian
- Somali
- Samoan
- Scots Gaelic
- Shona
- Sindhi
- Sundanese
- Swahili
- Tajik
- Tamil
- Telugu
- Thai
- Ukrainian
- Urdu
- Uzbek
- Vietnamese
- Welsh
- Xhosa
- Yiddish
- Yoruba
- Kinyarwanda
- Tatar
- Oriya
- Turkmen
- Uyghur
UDkt Yu Baafa neqembu elivela e-United States bashicilela i-athikili ejeni le-Gastroenterology Research kanye nokwenza
2025-02-11
UDokotela Yu Baofa kanye nethimba laseMelika elihlanganisiwe ngokuhlangene okuhlaziywa kwama-auto autoantibodies kuma-turouantibodies amaningi ama-antigences ahlotshaniswa nezimpawu zomdlavuza we-pancreaterology kanye nokwenza.
Inhloso yalolu cwaningo bekuwukuhlola ukubaluleka komtholampilo kwama-autoantibodies ngokumelene ne-GNA11, i-MSLN, i-GNAS, i-P16, i-SUI1, i-PENTE ku-pancreatic Cancer (PC). Ingqikithi yamasampula e-serum angama-33 avela ezigulini ze-PC kanye namasampula angama-45 e-serum avela ezilawulweni ezijwayelekile (i-NC) afakiwe, futhi izinhlobo eziyi-9 zama-autoatibodies zitholwe kusetshenziswa i-enzyme-lixhumanisa ne-Imunosorbent Assay (ELISA). Hlaziya usebenzisa amapharamitha amaningi ngefomu ngalinye noma elihlanganisiwe. Ngaphandle kwe-anti GNAS ne-Anti CalNuc, amazinga awo wonke amanye ama-autoantibodies ayephakeme kakhulu kunaleyo eseqenjini elijwayelekile lokulawula. Uma kuqhathaniswa neqembu elijwayelekile lokulawula (4.9%), imvamisa yama-autoantibodies amane, i-MSL, P16, i-PENTE, ne-SUI1, kukhuphuke kakhulu, ngama-30,3%, kanye ne-27.3%, ngokulandelana. Amandla walezi ze-autoantibodies ukuhlukanisa le ndawo ngaphansi kwamabanga we-roc curve (auc) kusuka ku-0.666 kuya ku-0.666 kuya ku-0.684, nge-anti-p16 (a anti-p16 (a anti-p184) no-0.857) ekhombisa ukusebenza okunamandla kakhulu kokuxilonga. Inhlanganisela ye-anti-msln ne-anti-P16 ingathuthukisa ukuzwela kokuxilongwa.
Ngaphezu kwalokho, zombili i-MSLN ne-Sui1 Autoantibodies yehle ezigulini ze-PC ngemuva kwe-chemotherapy. Ama-autoantibodies amane abhekene ne-MSLN, P16, i-SUI1 nePENTE bakhombise umaka angaba khona wokuthola umdlavuza we-pancreatic, okuthi yi-anti MSLN ne-anti P16 engcono kakhulu. Ukuhlanganiswa kwalezi zimoto ezimbili kukhombisa amandla anomnotho kakhulu futhi asebenzayo. Ukubaluleka kokuncipha kwe-autoantibodies ngokumelene ne-MSLN ne-SUI1 kuziguli ze-PC ngemuva kokuhlolwa kwe-chemotherapy.
Ucwaningo lwama-autoantibodies ahlobene ne-tumor ahlinzeka ngesethenjwa esibalulekile ekuhlolweni kusenesikhathi, ukuxilongwa, kanye nokwelashwa kwama-tumors. I-Academinian yu bataofa yafaka isimila autoantibodies ku-tumor yokwelashwa eminyakeni engaphezu kwengu-20 edlule.
